Porous Membranes – 2m2/g
FibroSelect – 10m2/g
Bead Resins – 40m2/g
Global demand for cheaper biotherapeutics drives the need for bioprocessing cost reduction, a significant proportion of which comes from chromatography reagents and their operation. Recent evolution of the biopharmaceutical market has drawn focus to the limitations of current purification operations demanding a step-change improvement in processes. Growth of the biosimilars and pharmerging markets, along with a trend to outsource more production is putting a spotlight on COGS. Additionally, early adopters of new technology focus not only on costs but also process efficiency, flexibility and convenience during manufacturing.
Puridify’s technology, FibroSelect – a novel chromatography reagent, offers significant advantages across key performance attributes that not only allow chromatography associated costs to be reduced by up to 90% but are also well aligned to meet the industry demands today and as the market evolves.
We have proven at research scale (0.2mL reagent) that the technology can operate at 50x throughput due to better permeability and fast mass transfer. This improves process economics by increasing productivity and is also beneficial when processing labile products. The reagent has shown better resistance than our competitors to impurity fouling and cleaning steps, a common cause of performance degradation over multiple cycles. The technology allows cheap and rapid bioprocess development due to uniform performance at all scales, promoting its adoption in industry.
Puridify Ltd. is a UCL spinout from the Advanced Centre for Biochemical Engineering based on technology developed during a collaborative research project with the STFC involving Dr Oliver Hardick, Stewart Dods, Prof. Bob Stevens and Dr Daniel G. Bracewell. The development of FibroSelect utilised specialty ultra scale-down (USD) technology developed at UCL in order to make use of representative process materials.
See the following papers for more information: